GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Study Examines Hemodynamic Disruptions in Infants with Hypoxic-Ischemic Encephalopathy During Perinatal Oxygen Deprivation

by GOAI
Share To

A recent study has examined the hemodynamic changes associated with hypoxic-ischemic encephalopathy (HIE) in infants, a condition that arises from oxygen and blood flow deprivation to the brain during the perinatal period. HIE is a severe complication of perinatal asphyxia, which often leads to multiorgan dysfunction and poses significant risks to neonatal health. The research focuses on understanding how these hemodynamic disruptions contribute to the progression of HIE and its broader impact on affected infants.

The findings highlight the critical role of impaired blood flow regulation in the development of HIE. Researchers observed that oxygen deprivation during birth triggers a cascade of physiological responses, including reduced cerebral perfusion and systemic circulation abnormalities. These disruptions exacerbate brain injury and can lead to long-term neurological deficits if not promptly addressed. The study underscores the importance of monitoring and managing hemodynamic parameters in neonates diagnosed with HIE to mitigate its effects on organ function and overall outcomes.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top